_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

In this three-part series, expert haemato-oncologists discuss MPNs, considering differences in patient and physician perceptions on the burden of disease, real-world evidence in MF, and how to change your approach based on a patient’s genetic mutations.

 

MF, myelofibrosis; MPN, myeloproliferative neoplasm.

HCP20-C040 August 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via uk.pa[email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]